InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,430.40
(
0.14%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.85
(
0.07%
)
Bitcoin
65,143.45
(
0.01%
)
Post# of 252254
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: DewDiligence post# 154212

Thursday, 12/27/2012 3:38:06 AM

Thursday, December 27, 2012 3:38:06 AM

Post# of 252254

Factoid: Teva has the lowest P/E ratio* of any consistently profitable drug/biotech company.

Corollary: Most investors don’t think thrice-weekly Copaxone is likely to be an effective lifecycle-management fix for the Copaxone franchise, as Teva contends.

Investors don't think Teva's strategy as a whole is convincing: its intention to focus on New Therapeutic Entity (NTE), no mention of exciting program in the pipeline, etc.



Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up